Clinical Trial Update: A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase I open-label study evaluating the safety and tolerability of elotuzumab in combination with lirilumab or urelumab in patients with multiple myeloma; the t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elotuzumab (elotuzumab)
• Urelumab (urelumab)
• lirilumab (lirilumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED